GlobalData estimates that the global leiomyosarcoma therapeutics market was valued at $53.4m in 2011, and is forecast to grow at a high Compound Annual Growth Rate (CAGR) of 9.2% over the next seven years to reach $108.2m by 2019. This fast growth is primarily attributed to the strength of the leiomyosarcoma pipeline, which contains five first-in-class molecules in the late stage of development.
GlobalData estimates that the global Multiple Sclerosis (MS) therapeutics market was valued at $9,237m in 2011. The global MS therapeutics, which includes Disease Modifying Drugs (DMDs) and drugs for symptom management, is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.2% over the next eight years, to reach $11,914m by 2019. The rapid growth of the market during 2006-2011 (13.6% CAGR) was mainly due to the growth in diagnosed and treated patients. The treated patient pool registered rapid growth due to the introduction of new diagnostic criteria called the McDonald criteria, which integrated MRI findings into clinical assessments and resulted in a greater number of confirmed MS diagnoses. In addition, the understanding of the disease’s pathogenesis has improved.
Singapore had a population of approximately 5.1 million and a low population growth rate of 1.8% in 2010. The available data for the age distribution of the population of Singapore indicates a decrease in the 0-19 year-old age group population, and an increase in the 60 years and above age group population from 2005 to 2020. The population in 0-19 age group is expected to decline from 24% of the total population in 2010 to 20% of the total population in 2020. However, the population in the 60 years and above age group is expected to increase from 14% in 2010 to 21% of the total population in 2020. An increase in the elderly population of Singapore will result in an drastic increase in the healthcare burden in the future. The population aged 60 years and above is increasing at a steady rate and is projected to reach approximately one million by 2020. Moreover, a decline in the population group of working age is an added concern for the future of Singapore’s economy. Thus, the low population growth rate and rising elderly population represent a challenge to the policy planners in Singapore.
The Utica shale has reported a significant increase in the leasing and drilling activities in Ohio in 2011. The exploration and development activities have gradually picked up in the Utica shale last year. Moreover, many oil and gas companies leased in this shale recently and have plans to start drilling soon.
The electricity consumed by the global lighting sector had increased from around 2.6 petawatt hours (PWh) in 2005 to 2.9 PWh in 2010. Lighting appliances consume approximately 19% of the total electricity generated. North America consumes the largest amount of electricity for lighting in the world. The region consumes 864 terawatt hours (TWh) of power for lighting in a year. Europe follows North America as the second largest consumer of power for lighting. Major countries such as the US, Canada and the UK have adopted energy efficient lighting products such as Compact Fluorescent Lamps (CFL) as a solution to reduce electricity consumption for lighting
The global market for compression therapy was valued at $2 billion in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5% to $2.7 billion in 2018, driven by the growing incidence of venous disease due to chronic wounds, a growing elderly population, diabetes and repeated wound trauma. The increase in awareness of venous diseases, aided by campaigns from various venous disease forums, societies and educational materials, and the use of compression therapy products as a preventive measure is also expected to encourage market growth.
Biopower is one of the major renewable sources of energy. Biopower uses organic matter such as sewage, municipal waste, wood residues, forest residues, fiber, and short-rotation crops and so on to generate electricity. The global biopower market is driven by supportive policies from various governments across the world. Governments worldwide are investing in biopower and related technologies to ensure stability and security of energy supply and to curb carbon emissions. In the wake of growing energy security and environmental concerns, support mechanisms in favor of biopower and related technologies are expected to be strengthened in most of the nations.
The report is an essential source of insight into global pulmonary embolism therapeutics, providing actionable analysis on the key trends affecting the market, including pipeline products. The report also provides insights into the prevalent competitive landscape and key players expected to significantly alter the market positioning of the current market leaders. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData estimates that the global rhabdomyosarcoma therapeutics market was valued at $37.8m in 2011, and is forecast to grow at slow pace with a Compound Annual Growth Rate (CAGR) of 2.4% over the next seven years to reach $45.8m by 2019. This slow growth is primarily attributed to the fact that the patient population shows a moderate to lower growth in the US, the UK, France and Italy. However, Germany, Spain and Japan show a negative trend over the years
The global infusion systems market was valued at $6 billion in 2010 and is forecast to grow to a value of $8.3 billion by 2017 at a Compound Annual Growth Rate (CAGR) of 4.7%. The market is forecast to grow due to the increase in the chronic pain patient population, advancements in the infusion pump technology with an increased focus on safety and the positive developments in the reimbursement scenario for infusion systems in the US market.